VERONA PHARMA PLC - ADR (VRNA) Fundamental Analysis & Valuation

NASDAQ:VRNA • US9250501064

106.91 USD
+0.12 (+0.11%)
At close: Oct 6, 2025
106.94 USD
+0.03 (+0.03%)
After Hours: 10/6/2025, 9:09:40 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VRNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall VRNA gets a fundamental rating of 3 out of 10. We evaluated VRNA against 193 industry peers in the Pharmaceuticals industry. VRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, VRNA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. VRNA Profitability Analysis

1.1 Basic Checks

  • In the past year VRNA has reported negative net income.
  • In the past year VRNA has reported a negative cash flow from operations.
  • In the past 5 years VRNA always reported negative net income.
  • In the past 5 years VRNA always reported negative operating cash flow.
VRNA Yearly Net Income VS EBIT VS OCF VS FCFVRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • With a decent Return On Assets value of -14.17%, VRNA is doing good in the industry, outperforming 63.08% of the companies in the same industry.
  • With a Return On Equity value of -29.18%, VRNA perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
ROA -14.17%
ROE -29.18%
ROIC N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
VRNA Yearly ROA, ROE, ROICVRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • VRNA has a better Gross Margin (95.15%) than 96.41% of its industry peers.
  • VRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRNA Yearly Profit, Operating, Gross MarginsVRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. VRNA Health Analysis

2.1 Basic Checks

  • VRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VRNA has been increased compared to 1 year ago.
  • The number of shares outstanding for VRNA has been increased compared to 5 years ago.
  • VRNA has a worse debt/assets ratio than last year.
VRNA Yearly Shares OutstandingVRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRNA Yearly Total Debt VS Total AssetsVRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 18.44 indicates that VRNA is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 18.44, VRNA belongs to the best of the industry, outperforming 90.26% of the companies in the same industry.
  • A Debt/Equity ratio of 0.87 indicates that VRNA is somewhat dependend on debt financing.
  • VRNA has a worse Debt to Equity ratio (0.87) than 71.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z 18.44
ROIC/WACCN/A
WACC9.28%
VRNA Yearly LT Debt VS Equity VS FCFVRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 10.71 indicates that VRNA has no problem at all paying its short term obligations.
  • VRNA's Current ratio of 10.71 is amongst the best of the industry. VRNA outperforms 83.08% of its industry peers.
  • VRNA has a Quick Ratio of 10.54. This indicates that VRNA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of VRNA (10.54) is better than 83.08% of its industry peers.
Industry RankSector Rank
Current Ratio 10.71
Quick Ratio 10.54
VRNA Yearly Current Assets VS Current LiabilitesVRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. VRNA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.54% over the past year.
  • VRNA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.86% yearly.
EPS 1Y (TTM)36.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.77%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • VRNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.72% yearly.
  • VRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 123.42% yearly.
EPS Next Y123.97%
EPS Next 2Y73.8%
EPS Next 3Y64.23%
EPS Next 5Y57.72%
Revenue Next Year1008.75%
Revenue Next 2Y342.34%
Revenue Next 3Y211.05%
Revenue Next 5Y123.42%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRNA Yearly Revenue VS EstimatesVRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
VRNA Yearly EPS VS EstimatesVRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

2

4. VRNA Valuation Analysis

4.1 Price/Earnings Ratio

  • VRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 48.49, VRNA can be considered very expensive at the moment.
  • VRNA's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. VRNA is cheaper than 67.18% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 25.11, VRNA is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 48.49
VRNA Price Earnings VS Forward Price EarningsVRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRNA Per share dataVRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • VRNA's earnings are expected to grow with 64.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.8%
EPS Next 3Y64.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VRNA Dividend Analysis

5.1 Amount

  • No dividends for VRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VRNA Fundamentals: All Metrics, Ratios and Statistics

VERONA PHARMA PLC - ADR

NASDAQ:VRNA (10/6/2025, 9:09:40 PM)

After market: 106.94 +0.03 (+0.03%)

106.91

+0.12 (+0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06
Earnings (Next)11-03
Inst Owners80.77%
Inst Owner Change-88.5%
Ins Owners4.64%
Ins Owner Change-1733.39%
Market Cap9.19B
Revenue(TTM)221.67M
Net Income(TTM)-81.19M
Analysts68.89
Price Target108.43 (1.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)75.16%
Min EPS beat(2)-4.58%
Max EPS beat(2)154.9%
EPS beat(4)1
Avg EPS beat(4)26.61%
Min EPS beat(4)-34.07%
Max EPS beat(4)154.9%
EPS beat(8)3
Avg EPS beat(8)-13.52%
EPS beat(12)4
Avg EPS beat(12)-12.45%
EPS beat(16)8
Avg EPS beat(16)2.57%
Revenue beat(2)2
Avg Revenue beat(2)24.91%
Min Revenue beat(2)9.73%
Max Revenue beat(2)40.08%
Revenue beat(4)4
Avg Revenue beat(4)58.05%
Min Revenue beat(4)8.73%
Max Revenue beat(4)173.67%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.55%
EPS NY rev (1m)2.01%
EPS NY rev (3m)147.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 48.49
P/S 41.47
P/FCF N/A
P/OCF N/A
P/B 33.04
P/tB 33.1
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)2.2
Fwd EY2.06%
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS2.58
BVpS3.24
TBVpS3.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.17%
ROE -29.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.15%
FCFM N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.14%
Cap/Sales 0.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.71
Quick Ratio 10.54
Altman-Z 18.44
F-Score4
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)19.84%
Cap/Depr(5y)14.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.77%
EPS Next Y123.97%
EPS Next 2Y73.8%
EPS Next 3Y64.23%
EPS Next 5Y57.72%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1008.75%
Revenue Next 2Y342.34%
Revenue Next 3Y211.05%
Revenue Next 5Y123.42%
EBIT growth 1Y57.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year125.44%
EBIT Next 3Y118.37%
EBIT Next 5YN/A
FCF growth 1Y-39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.98%
OCF growth 3YN/A
OCF growth 5YN/A

VERONA PHARMA PLC - ADR / VRNA FAQ

Can you provide the ChartMill fundamental rating for VERONA PHARMA PLC - ADR?

ChartMill assigns a fundamental rating of 3 / 10 to VRNA.


What is the valuation status of VERONA PHARMA PLC - ADR (VRNA) stock?

ChartMill assigns a valuation rating of 2 / 10 to VERONA PHARMA PLC - ADR (VRNA). This can be considered as Overvalued.


How profitable is VERONA PHARMA PLC - ADR (VRNA) stock?

VERONA PHARMA PLC - ADR (VRNA) has a profitability rating of 2 / 10.


How financially healthy is VERONA PHARMA PLC - ADR?

The financial health rating of VERONA PHARMA PLC - ADR (VRNA) is 5 / 10.